Bayer Healthcare LLC

Jianmin Chen

Clark Qun Pan

Thomas Barnett

John E Murphy

Deqian Wang

Jonathan S Strauss

Baisong Mei

Hendri Tjandra

Liang Tang

Jiang Tang

Deqian Wamg

This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.

Factor VIII conjugates

This invention relates to Factor VIII muteins that are covalently bound, at one or more predefined sites that are not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity, are capable of correcting human factor VIII deficiencies and have improved pharmacokinetic properties.

Site-directed modification of FVIII

Growing community of inventors

Concord, CA, United States of America

Jianmin Chen